Analysts expect Natera to report Q2 2026 revenue of $661.26 million and an EPS loss of $0.49, with the stock currently trading at $270.36, slightly above the $267.83 consensus price target.
Investors are primarily focused on Signatera oncology test volume growth and updates on Medicare reimbursement expansion via MolDx for seven additional cancer indications.
Following a record first quarter where the company processed over one million tests and raised its full-year 2026 revenue guidance, Wall Street is looking for a potential second consecutive guidance hike.
Continued gross margin expansion and the progress of the commercial launch of Signatera in Japan remain critical factors for sustaining the company's significant recent valuation gains.